---
document_datetime: 2023-09-21 19:44:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_en.pdf
document_name: bydureon-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.1289439
conversion_datetime: 2025-12-25 09:19:47.889851
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                                          | Route of Administration   | Immediate Packaging                                      | Content Concentration                | Pack size                                                                                               |
|------------------|-------------------|------------|------------------------------------------------------------------------------|---------------------------|----------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------|
| EU/1/11/696/001  | Bydureon          | 2 mg       | Powder and solvent for prolonged- release suspension for injection           | Subcutaneous use          | powder: vial (glass); solvent:pre-filled syringe (glass) | Powder 2 mg Solvent 0.65ml (3mg/ml)  | 4 single-dose kits (1 vial + 1 pre- filled syringe + 1 vial connector + 2 needles)                      |
| EU/1/11/696/002  | Bydureon          | 2 mg       | Powder and solvent for prolonged- release suspension for injection           | Subcutaneous use          | powder: vial (glass); solvent:pre-filled syringe (glass) | Powder 2 mg Solvent 0.65 ml (3mg/ml) | 12 (3 x 4) single- dose kits (1 vial + 1 pre-filled syringe + 1 vial connector + 2 needles) (multipack) |
| EU/1/11/696/003  | Bydureon          | 2 mg       | Powder and solvent for prolonged- release suspension for                     | Subcutaneous use          | cartridge(glass) in pre-filled pen                       | Powder 2 mg Solvent 0.65 ml (3mg/ml) | 4 pre-filled pens + 1 needle                                                                            |
| EU/1/11/696/004  | Bydureon          | 2 mg       | injection Powder and solvent for prolonged- release suspension for injection | Subcutaneous use          | cartridge(glass) in pre-filled pen                       | Powder 2 mg Solvent 0.65 ml (3mg/ml) | 12 (3 x 4) pre- filled pens + 3 needles (multipack)                                                     |
| EU/1/11/696/005  | Bydureon          | 2 mg       | Prolonged- release suspension for injection                                  | Subcutaneous use          | cartridge (glass) in pre-filled pen with needle          | 0.85 ml (2.35 mg/ml)                 | 4 pre-filled pens                                                                                       |
| EU/1/11/696/006  | Bydureon          | 2 mg       | Prolonged- release suspension for injection                                  | Subcutaneous use          | cartridge (glass) in pre-filled pen with needle          | 0.85 ml (2.35 mg/ml)                 | 12 (3 x 4) pre- filled pens (multipack)                                                                 |